These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19638456)

  • 1. Tumor endothelial cells join the resistance.
    Dudley AC; Klagsbrun M
    Clin Cancer Res; 2009 Aug; 15(15):4787-9. PubMed ID: 19638456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells.
    Xiong YQ; Sun HC; Zhang W; Zhu XD; Zhuang PY; Zhang JB; Wang L; Wu WZ; Qin LX; Tang ZY
    Clin Cancer Res; 2009 Aug; 15(15):4838-46. PubMed ID: 19638466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis as a therapeutic target in urothelial carcinoma.
    Pinto A; Redondo A; Zamora P; Castelo B; Espinosa E
    Anticancer Drugs; 2010 Nov; 21(10):890-6. PubMed ID: 20729712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma.
    Kuczynski EA; Kerbel RS
    Chin J Cancer; 2016 Nov; 35(1):97. PubMed ID: 27887628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
    Alfaro C; Suarez N; Gonzalez A; Solano S; Erro L; Dubrot J; Palazon A; Hervas-Stubbs S; Gurpide A; Lopez-Picazo JM; Grande-Pulido E; Melero I; Perez-Gracia JL
    Br J Cancer; 2009 Apr; 100(7):1111-9. PubMed ID: 19277038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug insight: VEGF as a therapeutic target for breast cancer.
    Schneider BP; Sledge GW
    Nat Clin Pract Oncol; 2007 Mar; 4(3):181-9. PubMed ID: 17327858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of antiangiogenesis therapy: bevacizumab and beyond.
    Cortés-Funes H
    Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted agents and systemic therapy in hepatocellular carcinoma.
    Ang C; O'Reilly EM; Abou-Alfa GK
    Recent Results Cancer Res; 2013; 190():225-46. PubMed ID: 22941024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis.
    Bono AV; Pannellini T; Liberatore M; Montironi R; Cunico SC; Cheng L; Sasso F; Musiani P; Iezzi M
    Anal Quant Cytol Histol; 2010 Jun; 32(3):136-45. PubMed ID: 20701066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic advances in women's cancers.
    Carroll AR; Coleman RL; Sood AK
    Front Biosci (Schol Ed); 2011 Jan; 3(1):82-97. PubMed ID: 21196359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How well do angiogenesis inhibitors work? Biomarkers of response prove elusive.
    Brower V
    J Natl Cancer Inst; 2009 Jun; 101(12):846-7. PubMed ID: 19509354
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting angiogenesis in bladder cancer.
    Elfiky AA; Rosenberg JE
    Curr Oncol Rep; 2009 May; 11(3):244-9. PubMed ID: 19336017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).
    Pazo-Cid RA; Lanzuela M; Esquerdo G; Pérez-Gracia JL; Antón A; Amigo G; Trufero JM; García-Otín AL; Martín-Duque P
    Clin Transl Oncol; 2012 Aug; 14(8):564-74. PubMed ID: 22855137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of angiogenesis in renal carcinoma].
    Bussolati B; Satolli MA; Camussi G
    G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
    Rini BI
    Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
    Greten TF; Manns MP; Malek N
    Z Gastroenterol; 2009 Jan; 47(1):55-60. PubMed ID: 19156592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
    Hagymási K; Tulassay Z
    Orv Hetil; 2010 Oct; 151(43):1763-8. PubMed ID: 20940115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interests in angiogenesis inhibitor drugs approved for the treatment of cancers].
    Bennis Y; Guillet B; Curti C; Pisano P
    Therapie; 2010; 65(2):95-105. PubMed ID: 20478241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma.
    Ohata Y; Shimada S; Akiyama Y; Mogushi K; Nakao K; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Tanabe M; Tanaka S
    Mol Cancer Ther; 2017 Jun; 16(6):1155-1165. PubMed ID: 28246302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma?
    Oseini AM; Roberts LR
    Expert Opin Ther Targets; 2009 Apr; 13(4):443-54. PubMed ID: 19335066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.